Dofetilide: A class III anti-arrhythmic drug for the treatment of atrial fibrillation

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2695-2704

  Torp Pedersen, C ^a   Brendorp, B ^a   Kober, L ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti arrhythmic; Atrial fibrillation; Chronic heart failure; Dofetilide; Myocardial infarction; Sinus rhythm

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYTOCHROME P450 3A4; DIGOXIN; DOFETILIDE; LIVER ENZYME; PLACEBO; POTASSIUM; SODIUM; SOTALOL;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; GUINEA PIG; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINUS RHYTHM; SURVIVAL RATE; TELEMETRY; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 0033764167     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2695     Document Type: Article

References (30)

1. A classification of anti-arrhythmic actions reassessed after a decade of new drugs
2. UK-68,798: A novel, potent and highly selective class III anti-arrhythmic agent which blocks potassium channels in cardiac cells
3. + current by dofetilide
4. Clinical and electrophysiologic effects of iv. dofetilide (UK-68, 798), a new class III anti-arrhythmic drug, in patients with angina pectoris
5. Dofetilide, a novel class III anti-arrhythmic agent
6. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group
7. Conversion of Atrial Fibrillation and Maintenance of Sinus Rhythm by Dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research of Atrial Fibrillation Dofetilide) Study
8. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study
9. Dofetilide: First of a new generation of class III agents
10. High-density mapping of electrically induced atrial fibrillation in humans
11. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes
12. Proarrhythmia with class III anti-arrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors and clinical implications
13. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
14. The long QT syndrome and torsade de pointes
15. The long QT syndrome: Ion channel diseases of the heart
16. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design and patient characteristics of the DIAMOND studies. Danish Investigations of Mortality on Dofetilide
17. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man
18. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and iv. administrations of dofetilide on ventricular repolarization
19. A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers
20. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data
21. Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts
22. Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs
23. Rate and concentration-dependent effects of UK-68,798, a potent new class III anti-arrhythmic, on canine Purkinje fibre action potential duration and V(max)
24. Rate- and site-dependent effects of propafenone, dofetilide, and the new I(Ks)-blocking agent chromanol 293b on individual muscle layers of the intact canine heart
25. Effects of the class III anti-arrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
26. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans
27. The Diamond Study Group: A Clinical Trial of Dofetilide in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction. The DIAMOND MI Study
28. Oral dofetilide improves quality of life: An EMERALD substudy
29. Effect of dofetilide on survival in patients with supraventricular arrhythmias
30. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators